골다공증에서 부갑상샘호르몬제의 작용 기전과 효능 = Mechanism and efficacy of parathyroid hormone in osteoporosis

다국어 초록 (Multilingual Abstract)

Background: Parathyroid hormone (PTH) and teriparatide, which is a PTH analog, are special options of osteoanabolic therapies for osteoporosis treatment. Their efficacy in improving the bone mineral density (BMD) and reducing fracture risk is considered to have a long-awaited justification.
Current Concepts: PTH is an 84-amino acid polypeptide that plays a key role in the calcium homeostasis of the human body. It yields anabolic effects on the bone by intermittent injections. During the first 6 months of PTH treatment, bone formation increases rapidly and bone resorption rises gradually. PTH is believed to be maximally anabolic during the anabolic window. In the phase III trial of teriparatide, significant reductions in vertebral and non-vertebral fractures were identified. Teriparatide has been studied in drug-induced osteoporosis, postmenopausal women with osteoporosis, and men with osteoporosis. The data derived from clinical trials with teriparatide showed an increase of the BMD in the treatment group compared to that of the placebo. Selective advantages on fracture healing have been shown in some studies; however, consensus on the relationship between teriparatide and bone healing is unclear.
Discussion and Conclusion: Teriparatide has been approved for osteoporosis treatment in various situations, including postmenopausal women, men with osteoporosis, and cases with glucocorticoid-induced osteoporosis.
Additionally, it can be useful in high risk for fracture groups, if fractures persist despite bone resorption inhibitor therapy, and if bone resorption inhibitor administration is difficult and contraindicated.

참고문헌 (Reference)

1 Cusano NE, "Therapy of osteoporosis in men with teriparatide" 2011 : 463675-, 2011

2 Orwoll ES, "The effect of teriparatide [human parathyroid hormone(1-34)] therapy on bone density in men with osteoporosis" 18 : 9-17, 2003

3 Yoo JI, "Teriparatide treatment in elderly patients with sacral insufficiency fracture" 102 : 560-565, 2017

4 Saag KG, "Teriparatide or alendronate in glucocorticoid-induced osteoporosis" 357 : 2028-2039, 2007

5 Gilsenan A, "Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study" 36 : 244-251, 2021

6 Bauer W, "Studies of calcium and phosphorus metabolism : V. A study of the bone trabeculae as a readily available reserve supply of calcium" 49 : 145-162, 1929

7 Jiang Y, "Recombinant human parathyroid hormone(1-34)[teriparatide] improves both cortical and cancellous bone structure" 18 : 1932-1941, 2003

8 Nakamura T, "Randomized teriparatide [human parathyroid hormone(PTH)1-34] once-weekly efficacy research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk" 97 : 3097-3106, 2012

9 Lindsay RS, "Hypothyroidism" 349 : 413-417, 1997

10 Finkelstein JS, "Effects of teriparatide retreatment in osteoporotic men and women" 94 : 2495-2501, 2009

11 Min HK, "Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures : a retrospective analysis of prospectively designed study" 30 : 2249-2256, 2019

12 Malouf-Sierra J, "Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture : final results of a 78-week randomized clinical trial" 32 : 1040-1051, 2017

13 Neer RM, "Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis" 344 : 1434-1441, 2001

14 Krishnan V, "Bone anabolic effects of sonic/indian hedgehog are mediated by bmp-2/4-dependent pathways in the neonatal rat metatarsal model" 142 : 940-947, 2001